Development of a human whole blood assay for prediction of cytokine release similar to anti-CD28 superagonists using multiplex cytokine and hierarchical cluster analysis-Reference-Cited by-同舟云学术

Development of a human whole blood assay for prediction of cytokine release similar to anti-CD28 superagonists using multiplex cytokine and hierarchical cluster analysis

Published:2011-11 Issue:11 Volume:11 Page:1697-1705
ISSN:1567-5769
Container-title:International Immunopharmacology
language:en
Short-container-title:International Immunopharmacology

Author:

Walker Mindi R.,Makropoulos Dorie A.,Achuthanandam Ram,Van Arsdell Scott,Bugelski Peter J.

Funder

Centocor R&D.

Publisher

Elsevier BV

Subject

Pharmacology,Immunology,Immunology and Allergy

Reference53 articles.

1. Common toxicity criteria (CTC) v2.0,1999

2. Recent advances in the understanding of drug-mediated infusion reactions and cytokine release syndrome;Walker;Curr Opin Drug Discov Devel,2010

3. Inter-mouse strain differences in the in vivo anti-CD3 induced cytokine release;Ferran;Clin Exp Immunol,1991

4. Cytokine storm in a mouse model of IgG-mediated hemolytic transfusion reactions;Hod;Blood,2008

5. A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees;Hsu;Transplantation,1999

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients;International Immunopharmacology;2021-01

2. The blood endothelial cell chamber – An innovative system to study immune responses in drug development;International Immunopharmacology;2021-01

3. Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms – Report of an international collaborative study;Cytokine: X;2020-12

4. An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules;PLOS ONE;2018-10-15

5. Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community;BioDrugs;2017-04-24